2 weeks Ago By Defense World Staff
LPL Financial LLC raised its holdings in Cytokinetics, Incorporated ( NASDAQ:CYTK – Free Report ) by 6.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,988 shares of the biopharmaceutical company’s stock after buying an additional 870 shares during the quarter.
LPL Financial LLC’s holdings in Cytokinetics were worth $658,000 as of its most recent SEC filing. Several other hedge funds have also recently added to or reduced their stakes in CYTK. abrdn plc raised its position in Cytokinetics by 29.
4% in the 4th quarter. abrdn plc now owns 450,513 shares of the biopharmaceutical company’s stock valued at $21,192,000 after purchasing an additional 102,457 shares during the last quarter. Fisher Asset Management LLC grew its stake in shares of Cytokinetics by 13.
7% during the fourth quarter. Fisher Asset Management LLC now owns 616,492 shares of the biopharmaceutical company’s stock worth $29,000,000 after purchasing an additional 74,208 shares during the period. Exome Asset Management LLC bought a new stake in shares of Cytokinetics in the 3rd quarter valued at about $3,093,000.
Impax Asset Management Group plc grew its holdings in shares of Cytokinetics by 40.0% in the 4th quarter. Impax Asset Management Group plc now owns 175,000 shares of the biopharmaceutical company’s stock valued at $8,232,000 after buying an additional 50,000 shares during the period.
Finally, Great Lakes Advisors LLC bought a new stake in shares of Cytokinetics in the fourth quarter worth about $1,580,000. Analyst Upgrades and Downgrades CYTK has been the subject of a number of research reports. Evercore ISI upgraded Cytokinetics to a “strong-buy” rating in a report on Friday, February 7th.
Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 price target on shares of Cytokinetics in a research report on Tuesday, April 8th. Stifel Nicolaus initiated coverage on shares of Cytokinetics in a research note on Wednesday, January 22nd.
They set a “buy” rating and a $80.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $120.
00 target price on shares of Cytokinetics in a research note on Monday. Finally, Morgan Stanley set a $67.00 target price on Cytokinetics in a report on Friday, March 7th.
Two research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Cytokinetics currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.63.
Cytokinetics Stock Performance NASDAQ CYTK opened at $38.00 on Thursday. Cytokinetics, Incorporated has a 1 year low of $32.
74 and a 1 year high of $68.44. The firm’s 50 day simple moving average is $42.
31 and its 200 day simple moving average is $47.40. The company has a current ratio of 9.
28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93.
The firm has a market capitalization of $4.53 billion, a price-to-earnings ratio of -7.06 and a beta of 0.
94. Cytokinetics ( NASDAQ:CYTK – Get Free Report ) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.
26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.03.
The business had revenue of $16.93 million during the quarter, compared to the consensus estimate of $14.26 million.
As a group, research analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year. Insider Buying and Selling at Cytokinetics In related news, EVP Fady Ibraham Malik sold 2,000 shares of the firm’s stock in a transaction on Tuesday, February 4th.
The stock was sold at an average price of $48.06, for a total transaction of $96,120.00.
Following the sale, the executive vice president now owns 116,071 shares of the company’s stock, valued at $5,578,372.26. This trade represents a 1.
69 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink . Also, EVP Andrew Callos sold 3,341 shares of the company’s stock in a transaction dated Thursday, March 6th.
The stock was sold at an average price of $43.27, for a total value of $144,565.07.
Following the completion of the transaction, the executive vice president now directly owns 64,434 shares of the company’s stock, valued at approximately $2,788,059.18. The trade was a 4.
93 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold 88,360 shares of company stock worth $3,643,645 over the last quarter.
Corporate insiders own 3.40% of the company’s stock. Cytokinetics Profile ( Free Report ) Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Recommended Stories Five stocks we like better than Cytokinetics What is Short Interest? How to Use It Can IBM’s Q1 Earnings Spark a Breakout for the Stock? Find and Profitably Trade Stocks at 52-Week Lows S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Earnings Per Share Calculator: How to Calculate EPS Fundamentally Sound, These 5 Stocks Sold Off Anyway Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter .
.
